Latest news with #Arbutus
The Market Online
5 days ago
- Business
- The Market Online
Datametrex acquires Arbutus Health and Wellness, expands Canadian healthcare footprint
Datametrex AI (TSXV:DM) has acquired Arbutus Health and Wellness Inc., a multidisciplinary medical clinic for 11 million shares Arbutus offers a comprehensive range of medical services under one roof, including walk-in care, family medicine, and skin laser treatments The company plans to continue investing in healthcare innovation and infrastructure Datametrex AI Ltd. stock (TSXV:DM) last traded at $0.12 Technology and healthcare-focused company, Datametrex AI (TSXV:DM) announced the acquisition of Arbutus Health and Wellness Inc., a multidisciplinary medical clinic based in Vancouver, British Columbia. The acquisition marks a major move by Datametrex to deepen its presence in the Canadian healthcare market. Arbutus Health and Wellness offers a comprehensive range of medical services under one roof, including walk-in care, family medicine, skin laser treatments, and other specialty healthcare services. Once fully operational, the clinic will be staffed by licensed healthcare professionals, enabling patients to access multiple services without the need for multiple referrals—a model aimed at improving efficiency and patient experience. Under the terms of the agreement, Datametrex acquired 100 per cent of the issued and outstanding shares of Arbutus Health in exchange for 11 million common shares of Datametrex, valued at $0.10 per share. Arbutus is now a wholly-owned subsidiary of Datametrex. Datametrex has not assumed any debt from Arbutus as part of the transaction. The acquisition does not constitute a fundamental change to Datametrex's business operations, nor is it expected to result in a change of control of the company. 'We are excited to finalize this agreement and are eager to integrate the Arbutus Health team into Datametrex,' Datametrex's CEO, Paul Haber said in a news release. 'This acquisition marks a key milestone in broadening our product portfolio and enhancing our presence in the healthcare sector.' The company plans to continue investing in healthcare innovation and infrastructure, leveraging its technological expertise to support the clinic's operations and patient services. Datametrex develops innovative solutions across technology, artificial intelligence and healthcare to enhance operational efficiencies and business outcomes. Datametrex AI Ltd. stock (TSXV:DM) last traded at $0.12 and though it has risen more than 9 per cent this week, it has lost more than 73 per cent since June 2024. Join the discussion: Find out what everybody's saying about this potentially undervalued microcap stock on the Datametrex AI Ltd. Bullboard, and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Vancouver Sun
27-05-2025
- Business
- Vancouver Sun
City of Vancouver abandons controversial Kitsilano social housing project
The City of Vancouver has scrapped plans to build a controversial social housing building on city-owned property in Kitsilano. The 13-storey project at 8th and Arbutus was pitched four years ago as a partnership between the city and the province to build 129 affordable homes for those at risk of homelessness, with on-site supports including health-care. The development, in a residential neighbourhood near an elementary school, children's playground, and women's recovery house, was fiercely opposed by a well-organized neighbourhood group that went to court to halt the project after it was approved by Vancouver's previous council in 2022. In an email on Tuesday, Vancouver Mayor Ken Sim said: 'It's clear this location wasn't the right fit for the scale and type of housing that was proposed. … The number of individuals with substantive mental health and addictions issues in one location would have been a significant concern due to the site's proximity to an elementary school and women's recovery centre.' A daily roundup of Opinion pieces from the Sun and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Informed Opinion will soon be in your inbox. Please try again Interested in more newsletters? Browse here. The project died quietly late last month, when the City of Vancouver agreed to a consent order with the neighbourhood group, agreeing to rescind the rezoning approved by the previous mayor and council in 2022, and quashing the related development permit and housing agreement. The order was dated April 30 and signed by a B.C. Supreme Court judge and lawyers for the city and the residents' group. But in December , the B.C. Court of Appeal ruled that law was unconstitutional. The province did not appeal to the Supreme Court of Canada, said the Kitsilano Coalition's lawyer Peter Gall, 'they just accepted that they overreached.' In an emailed statement, the City of Vancouver said it 'accepts the position of the Kitsilano Coalition for Children and Family Safety that the public hearing held in June and July 2022' to rezone the property 'was procedurally flawed.' Sim said Tuesday that he would not speculate on the future of the city-owned property, which is a block away from a future Broadway subway station. The city has 'reached out to the province to explore options for smaller and better-resourced supportive housing projects to replace the units originally planned for Arbutus,' Sim said. 'We have not yet received a response.' Ravi Kahlon, B.C.'s minister of housing and a supporter of the Arbutus project, said Tuesday that its cancellation was 'disappointing, because we know there's people right now in that community sleeping in encampments, sleeping in parks, and we need to get people indoors to get them supports.' 'Now, we'll have to find another parcel of land or possibly purchase something to build supportive housing,' Kahlon said. 'But that community needs it, and we're going to be pursuing other opportunities in that community.' Cheryl Grant, a spokesperson for the Kitsilano coalition, said she would 'love to see a mix of housing' developed on the property, that could include market and non-market housing for seniors and families. 'We're really encouraged by this. We believe this is a step forward with Ken Sim and the city to open up the conversation, revisit the property, and find the right form of housing,' Grant said. 'The plan there should really make sense for the community.' The project had been championed by B.C. Premier David Eby. When Eby was housing minister in 2022, shortly before the rezoning came to Vancouver's previous council for a decision, he said he was sympathetic to the concerns of neighbourhood residents , many of whom are constituents of his Vancouver-Point Grey riding, an area that has not had a lot of this kind of social housing built in recent years. But Eby said he was confident the Arbutus project would work well once it started operating, and he was committed to taking 'action' to make any needed changes if problems arose after its opening. 'We really need this housing to work and … build more of it. So if this goes sideways, then the city council are going to be reluctant to approve it, the neighbours are going to be more reluctant to have housing like this, and so on,' Eby told Postmedia News in 2022 . 'So it's a long-term plan we have here, and it requires the success of projects like this.' Sim and his party ABC Vancouver, which controls a majority on city council, drew both criticism and applause earlier this year when they approved a plan to halt construction of new supportive housing developments. Sim said the goal was to reduce the concentration of this type of housing in Vancouver, which has 77 per cent of Metro's supportive housing but only 25 per cent of its population. With files from Alec Lazenby dfumano@
Yahoo
03-03-2025
- Business
- Yahoo
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA®. Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the U.S. and Europe indicating that the samples contain LNPs falling under the protective scope of the claims of their lipid composition patents. The cases are: Canada: Federal Court of Canada File No. T-704-25, seeking a permanent injunction and damages or, if Genevant so elects, an accounting of Moderna's profits, attributable to infringement of Canadian Patent No. 2,721,333. Japan: Tokyo District Court Case No. 2025 (Wa) 70079, seeking a permanent injunction and reasonable royalty for infringement of Japanese Patent No. 5,475,753. Switzerland: filing a case seeking a permanent injunction and monetary relief, which upon later choice of Genevant and Arbutus can include surrender of profits, damages or a reasonable royalty, for infringement of EP 2 279 254. Unified Patent Court (UPC): Case 10280/2025, seeking permanent and provisional injunctions, as well as monetary damages, which can include recovery of Moderna's unfair profits, from infringement of EP 2 279 254. UPC: Case 10284/2025, seeking permanent and provisional injunctions, as well as monetary damages, which can include recovery of Moderna's unfair profits, from infringement of EP 4 241 767. The UPC actions together seek relief for: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland/Liechtenstein, and Turkey. Today's actions expand on Arbutus and Genevant's ongoing enforcement proceeding in the U.S. District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six U.S. patents in the manufacture and sale of Spikevax®. A jury trial is currently scheduled for September 2025. It is well established in the scientific literature that the most significant technological hurdle to developing and deploying medicines using mRNA is engineering a safe and effective way to deliver the mRNA to human cells. Scientists at Arbutus and Genevant have spent years developing and refining LNP delivery technology, which has been licensed for various applications to many different third parties, including Moderna. Arbutus and Genevant's LNP technology relies on microscopic particles built from four carefully selected types of fat-like molecules to shelter and protect mRNA molecules and to enable them to travel through the human body to a target cell and through the target cell's membrane before releasing the mRNA. Without this crucial delivery technology, mRNA would quickly degrade in the body and be ineffective. About Genevant Sciences Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, a robust lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. Genevant's scientists have pioneered LNP delivery of nucleic acids for over 20 years, and Genevant's LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit About Arbutus Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The company is currently developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV). Through its ownership stake in and license agreement with Genevant, Arbutus is also focused on maximizing opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. For more information, visit Forward-Looking Statements and Information This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include, but are not limited to, statements about: Arbutus' plans with respect to the ongoing patent litigation matters. Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law. CONTACT: Contact: Pete Zorn
Associated Press
03-03-2025
- Business
- Associated Press
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax® and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA®. Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the U.S. and Europe indicating that the samples contain LNPs falling under the protective scope of the claims of their lipid composition patents. The cases are: Canada: Federal Court of Canada File No. T-704-25, seeking a permanent injunction and damages or, if Genevant so elects, an accounting of Moderna's profits, attributable to infringement of Canadian Patent No. 2,721,333. Japan: Tokyo District Court Case No. 2025 (Wa) 70079, seeking a permanent injunction and reasonable royalty for infringement of Japanese Patent No. 5,475,753. Switzerland: filing a case seeking a permanent injunction and monetary relief, which upon later choice of Genevant and Arbutus can include surrender of profits, damages or a reasonable royalty, for infringement of EP 2 279 254. Unified Patent Court (UPC): Case 10280/2025, seeking permanent and provisional injunctions, as well as monetary damages, which can include recovery of Moderna's unfair profits, from infringement of EP 2 279 254. UPC: Case 10284/2025, seeking permanent and provisional injunctions, as well as monetary damages, which can include recovery of Moderna's unfair profits, from infringement of EP 4 241 767. The UPC actions together seek relief for: Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland/Liechtenstein, and Turkey. Today's actions expand on Arbutus and Genevant's ongoing enforcement proceeding in the U.S. District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six U.S. patents in the manufacture and sale of Spikevax®. A jury trial is currently scheduled for September 2025. It is well established in the scientific literature that the most significant technological hurdle to developing and deploying medicines using mRNA is engineering a safe and effective way to deliver the mRNA to human cells. Scientists at Arbutus and Genevant have spent years developing and refining LNP delivery technology, which has been licensed for various applications to many different third parties, including Moderna. Arbutus and Genevant's LNP technology relies on microscopic particles built from four carefully selected types of fat-like molecules to shelter and protect mRNA molecules and to enable them to travel through the human body to a target cell and through the target cell's membrane before releasing the mRNA. Without this crucial delivery technology, mRNA would quickly degrade in the body and be ineffective. About Genevant Sciences Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, a robust lipid nanoparticle (LNP) patent portfolio, and decades of experience and expertise in nucleic acid drug delivery and development. Genevant's scientists have pioneered LNP delivery of nucleic acids for over 20 years, and Genevant's LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved systemic RNA-LNP product (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit About Arbutus Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease. The company is currently developing imdusiran (AB-729) for the treatment of chronic hepatitis B (cHBV). Through its ownership stake in and license agreement with Genevant, Arbutus is also focused on maximizing opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. For more information, visit Forward-Looking Statements and Information This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). Forward-looking statements in this press release include, but are not limited to, statements about: Arbutus' plans with respect to the ongoing patent litigation matters. Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
